SCHEMBL25868217

SCHEMBL25868217

CCCCn1c(=O)oc2ccc(-c3ccc(OC(C)(C)P)cc3)cc21

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
THRB P10828 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TSHR P16473 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
KMO O15229 1/20 0.43
TSPO P30536 1/20 0.42
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25865015 0.88 TP53 (0.47) MAPTTP53SMN1; SMN2THRBTDP1
SCHEMBL25869117 0.82 TSPO (0.52) TSPO
SCHEMBL25868038 0.82 ALDH1A1 (0.46) MAPTTP53SMN1; SMN2THRBTDP1
SCHEMBL25865022 0.81 ALDH1A1 (0.46) MAPTTP53SMN1; SMN2THRBTDP1
SCHEMBL25868267 0.80 TSPO (0.49) TSPO
SCHEMBL22314498 0.77 MAPT (0.53) MAPTTP53SMN1; SMN2THRBTDP1
SCHEMBL25868162 0.76 SMN1; SMN2 (0.44) MAPTTP53SMN1; SMN2THRBTDP1
SCHEMBL22314500 0.76 TP53 (0.44) MAPTTP53SMN1; SMN2THRBTDP1
SCHEMBL25865003 0.76 TSPO (0.47) ALDH1A1KMOTSPO
SCHEMBL22314889 0.75 TSPO (0.46) ALDH1A1KMOTSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B MAPT 670/4885TP53 4487/4885SMN1; SMN2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.